Evidence map›Paper›PMID 41321337›Full record

ArticleChina CDC weekly2025

Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease with Clinically Significant Fibrosis in Obese Patients with Type 2 Diabetes Mellitus - China, 2017-2024.

Yuping Chen, Xiao Liang, Yuxia Qi, Chuan Liu, Bingtian Dong, Xia Li, Jie Shen, Xiqiao Zhou, Xuan Liang, Minghua Zheng and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuping Chen *Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Zhongda Hospital, Medical School, Southeast University; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University); Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University; State Key Laboratory of Digital Medical Engineering, Nanjing City, Jiangsu Province, China.
Xiao Liang *Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, China.
Yuxia Qi *Qingdao Public Health Clinical Center, Qingdao City, Shandong Province, China.
Chuan LiuLiver Disease Center of Integrated Traditional Chinese and Western Medicine, Zhongda Hospital, Medical School, Southeast University; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University); Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University; State Key Laboratory of Digital Medical Engineering, Nanjing City, Jiangsu Province, China.
Bingtian DongThe First Affiliated Hospital of Anhui Medical University, Hefei City, Anhui Province, China.
Xia LiNational Clinical Research Center for Metabolic Diseases; Key Laboratory of Diabetes Immunology, Ministry of Education; The Second Xiangya Hospital of Central South University, Changsha City, Hunan Province, China.
Jie ShenShunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan City, Guangdong Province, China.
Xiqiao ZhouAffiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing City, Jiangsu Province, China.
Xuan LiangThe Sixth People's Hospital of Shenyang, Shenyang City, Liaoning Province, China.
Minghua ZhengMAFLD Research Center, the First Affiliated Hospital of Wenzhou Medical University; Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou City, Zhejiang Province, China.
Huating LiShanghai Belt and Road International Joint Laboratory for Intelligent Prevention and Treatment of Metabolic Disorders, Department of Computer Science and Engineering, School of Electronic, Information, and Electrical Engineering, Shanghai Jiao Tong University; Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Diabetes Institute; Shanghai Clinical Center for Diabetes, Shanghai, China.
Vincent Wai-Sun WongMedical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Zobair M YounossiGlobal NASH Council, Washington, DC, USA; Center for Outcomes Research in Liver Disease, Washington, DC, USA.
Yuemin NanDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Xiaolong QiLiver Disease Center of Integrated Traditional Chinese and Western Medicine, Zhongda Hospital, Medical School, Southeast University; Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University); Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University; State Key Laboratory of Digital Medical Engineering, Nanjing City, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: Metabolic dysfunction-associated steatotic liver disease (MASLD) with clinically significant fibrosis substantially elevates the risk of liver-related complications and mortality. The American Diabetes Association consensus report specifically recommends systematic risk stratification for MASLD and hepatic fibrosis in patients with type 2 diabetes mellitus (T2DM), with particular emphasis on those presenting with obesity. What is added by this report?: This multicenter study demonstrates that obese patients with T2DM exhibit a substantially elevated prevalence of MASLD with clinically significant fibrosis compared to their non-obese counterparts (26.7% What are the implications for public health practice?: Our findings underscore the critical need for routine screening and integrated management of MASLD with clinically significant fibrosis in patients with T2DM, particularly those presenting with obesity and multiple cardiometabolic risk factors.

Indexed as

Cardiometabolic risk factorsMASLD with clinically significant fibrosisObesity and diabetesPrevalence

Identifiers

PMID41321337
PMCPMC12660146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.